Skip to main content
. 2014 Jan 6;27(3):302–311. doi: 10.1111/tri.12252

Figure 1.

Figure 1

Study design. *Basiliximab induction allowed as of July 2008 by protocol amendment; EC-MPS: Myfortic; CNI + CsA: Neoral; Tx: transplant; BSL: baseline.